N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neuroblastoma [clinicaltrials:NCT00093353]
N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neuroblastoma [clinicaltrials:NCT00093353]
Bio2RDF identifier
NCT00093353
Bio2RDF namespace
clinicaltrials
Bio2RDF uri
http://bio2rdf.org/clinicaltrials:NCT00093353
identifiers.org URI
anticipated enrollment [clinicaltrials_vocabulary:anticipated-enrollment]
authority [clinicaltrials_vocabulary:authority]
brief summary [clinicaltrials_vocabulary:brief-summary]
RATIONALE: Drugs used i ...... resistant neuroblastoma.
brief title [clinicaltrials_vocabulary:brief-title]
N2003-01: Irinotecan, Temozolo ...... ent or Resistant Neuroblastoma
collaborator [clinicaltrials_vocabulary:collaborator]
condition [clinicaltrials_vocabulary:condition]
condition browse [clinicaltrials_vocabulary:condition-browse]
condition mesh [clinicaltrials_vocabulary:condition-mesh]
country [clinicaltrials_vocabulary:country]
detailed description [clinicaltrials_vocabulary:detailed-description]
OBJECTIVES:
Prim ...... tudy within 1.25
years.
download date [clinicaltrials_vocabulary:download-date]
ClinicalTrials.gov processed this data on August 10, 2015
eligibility [clinicaltrials_vocabulary:eligibility]
firstreceived date [clinicaltrials_vocabulary:firstreceived-date]
2004-10-06T00:00:00Z
has expanded access [clinicaltrials_vocabulary:has-expanded-access]
intervention [clinicaltrials_vocabulary:intervention]
intervention browse [clinicaltrials_vocabulary:intervention-browse]
is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]
keyword [clinicaltrials_vocabulary:keyword]
disseminated neuroblastoma
drug/agent toxicity by tissue/organ
recurrent neuroblastoma
lastchanged date [clinicaltrials_vocabulary:lastchanged-date]
2010-10-14T00:00:00Z
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
link [clinicaltrials_vocabulary:link]
location [clinicaltrials_vocabulary:location]
nct id [clinicaltrials_vocabulary:nct-id]
NCT00093353
official title [clinicaltrials_vocabulary:official-title]
A Phase I Study Of Oral Irinot ...... istant High-Risk Neuroblastoma
org study id [clinicaltrials_vocabulary:org-study-id]
CDR0000373759
overall official [clinicaltrials_vocabulary:overall-official]
overall status [clinicaltrials_vocabulary:overall-status]
oversight [clinicaltrials_vocabulary:oversight]
phase [clinicaltrials_vocabulary:phase]
primary completion date [clinicaltrials_vocabulary:primary-completion-date]
2006-07-01T00:00:00Z
responsible party [clinicaltrials_vocabulary:responsible-party]
secondary id [clinicaltrials_vocabulary:secondary-id]
P01CA081403
source [clinicaltrials_vocabulary:source]
start date [clinicaltrials_vocabulary:start-date]
2004-05-01T00:00:00Z
study design [clinicaltrials_vocabulary:study-design]
study type [clinicaltrials_vocabulary:study-type]
url [clinicaltrials_vocabulary:url]
verification date [clinicaltrials_vocabulary:verification-date]
2009-05-01T00:00:00Z
identifier
clinicaltrials:NCT00093353
title
N2003-01: Irinotecan, Temozolo ...... ent or Resistant Neuroblastoma
@en
type
label
N2003-01: Irinotecan, Temozolo ...... a [clinicaltrials:NCT00093353]
@en